Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.61 |
| ▸ | BRD4 | O60885 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20779009 | 1.00 | CRBN (0.62) | CRBNDDB1BRD4CNR2IKZF3 | |
| SCHEMBL20774154 | 1.00 | CRBN (0.62) | CRBNDDB1BRD4CNR2IKZF3 | |
| SCHEMBL30899453 | 1.00 | CRBN (0.62) | CRBNDDB1BRD4CNR2IKZF3 | |
| SCHEMBL30899433 | 1.00 | CRBN (0.62) | CRBNDDB1BRD4CNR2IKZF3 | |
| SCHEMBL30899452 | 1.00 | CRBN (0.62) | CRBNDDB1BRD4CNR2IKZF3 | |
| SCHEMBL30899429 | 1.00 | CRBN (0.62) | CRBNDDB1BRD4CNR2IKZF3 | |
| SCHEMBL22158624 | 0.83 | CRBN (0.58) | CRBNDDB1BRD4IKZF3 | |
| SCHEMBL22158625 | 0.83 | CRBN (0.58) | CRBNDDB1BRD4IKZF3 | |
| SCHEMBL24745153 | 0.82 | CRBN (0.52) | CRBNDDB1BRD4IKZF3 | |
| SCHEMBL20778965 | 0.80 | CRBN (0.53) | CRBNDDB1BRD4IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679026-A1 | GLUTARIMIDE | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| CN-111278815-A | Glutarimide | C4医药公司 | 2020-06-12 | — | — | CN | claimed |
| WO-2019043214-A1 | GLUTARIMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | claimed |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118108706-A | Glutarimide | C4医药公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-111278815-B | Glutarimide | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| EP-3679026-A1 | GLUTARIMIDE | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111278815-A | Glutarimide | C4医药公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2019043214-A1 | GLUTARIMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043214-A1 | GLUTARIMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802131-B2 | Glutarimides for medical treatment | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885BRD4 891/4885 |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885BRD4 891/4885 |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885BRD4 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.